Balyasny Asset Management
MDCO

Balyasny Asset Management’s Medicines Co MDCO Stock Holding History

Balyasny Asset Management’s Portfolio MDCO Stock Details MDCO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-405,000
Closed -$11.3M – 1841
2019
Q1 		$11.3M Buy
405,000
+45,000
+13% +$1.06M 0.08% 360
2018
Q4 		$6.89M Sell
360,000
-170,500
-32% -$3.97M 0.05% 443
2018
Q3 		$17.8M Buy
+530,500
New +$20M 0.08% 334
2017
Q3 		– Sell
-400,000
Closed -$15.2M – 2182
2017
Q2 		$15.2M Buy
+400,000
New +$17.8M 0.06% 401

Other funds holding MDCO

GT
Glenmede Trust Philadelphia, Pennsylvania $22.7B AUM

Balyasny Asset Management's MDCO Position: Q1 2020 in Review

Balyasny Asset Management sold out of Medicines Co (MDCO) in Q1 2020, closing a stake of 189,165 shares — an estimated $16.1M sold.

Balyasny Asset Management first reported a position in MDCO in Q3 2013 and held it in 11 quarters. The position peaked at $16.1M in Q4 2019. 1 fund tracked by Wall St. Rank holds MDCO as of Q1 2020.

  • Balyasny Asset Management reported no remaining Medicines Co position as of Q1 2020 after selling out during the quarter.
  • Balyasny Asset Management sold 189,165 Medicines Co shares in Q1 2020, an estimated $16.1M.
  • Balyasny Asset Management first reported a position in Medicines Co in Q3 2013 and held it in 11 quarters.
  • Balyasny Asset Management's Medicines Co position peaked at $16.1M in Q4 2019.
  • 1 fund tracked by Wall St. Rank held Medicines Co as of Q1 2020.

Based on Balyasny Asset Management's 13F filing for Q1 2020, filed 15 May 2020.